Study demonstrates a connection between a common chemical and Parkinson's disease

A University of Kentucky faculty member is a contributing author on a new study demonstrating a connection between a common solvent chemical and Parkinson's disease. Dr. Franca Cambi of the UK Kentucky Neuroscience Institute collaborated with researchers from across the U.S. on a paper recently published in the Annals of Neurology. The novel study looked at a cohort of human twins wherein one twin had been occupationally exposed to trichloroethylene (TCE) and other chemicals believed to be linked to development of Parkinson's.

TCE has been previously linked to Parkinson's disease through prior research by University of Kentucky authors and others, including the 2008 paper "Trichloroethylene: Parkinsonism and complex 1 mitochondrial ", and the 2010 paper "Trichloroethylene induces dopaminergic in Fisher 344 rats". The 2008 paper was based upon a study of factory workers in a facility using chemicals that have been linked to development of Parkinson's disease.

In the most recent paper, the authors demonstrated that in addition to TCE, increase in Parkinson's disease risk is also associated with exposure to percholorethylene (PERC) and (CCI4).

The current epidemiological study, led by Drs. Samuel Goldman and Caroline Tanner of The Parkinson's Institute in Sunnyvale, Ca., investigated exposure to TCE, PERC and CCI4 as they related to risk of developing Parkinson's disease. The team interviewed 99 from the National Academy of Sciences/National Research Council Veteran Twins Cohort in which one twin had Parkinson's and one didn't, inquiring about lifetime occupations and hobbies. Lifetime exposures to six specific solvents previously linked to Parkinson's in medical literature -- n-hexane, xylene, toluene, CCl4, TCE and PERC -- were inferred for each job or hobby typically involving exposure to the chemicals.

While prior research has indicated a link between TCE exposure and Parkinson's disease, the current findings are the first to report a statistically significant association -- a more than six-fold increased risk. Researchers also found that exposure to PERC and CCI4 tended toward significant risk of developing the disease.

This study focused on occupational exposures, but the solvents under investigation are pervasive in the environment. Lead author Goldman concluded: "Our findings, as well as prior case reports, suggest a lag time of up to 40 years between TCE exposure and onset of Parkinson's, providing a critical window of opportunity to potentially slow the disease process before clinical symptoms appear."

Occupational or environmental exposure to TCE, PERC and CCI4 is common due to the extensive use of the chemicals in dry-cleaning solutions, adhesives, paints, and carpet cleaners. Despite the Food and Drug Administration (FDA) banning the use of TCE as a general anesthetic, skin disinfectant, and coffee decaffeinating agent in 1977, it is still widely used today as a degreasing agent. In the U.S., millions of pounds of TCE are still released into the environment each year and it is the most common organic contaminant found in ground water, detected in up to 30 percent of drinking water supplies in the country.

The National Institute of Neurological Disorders and Stroke (NINDS) estimates that as many as 500,000 Americans have Parkinson's disease and more than 50,000 new cases are diagnosed annually. While there is much debate regarding the causes of , studies suggest that genetic and environmental factors likely trigger the disease - which is characterized by symptoms such as limb tremors, slowed movement, muscle stiffness, and speech impairment. Several studies have reported that to solvents may increase risk of Parkinson's, but research assessing specific agents is limited.

More information: "Solvent Exposures and Parkinson's Disease Risk in Twins"; Samuel M Goldman, Patricia J Quinlan, G Webster Ross, Connie Marras, Cheryl Meng, Grace S Bhudhikanok, Kathleen Comyns, Monica Korell, Anabel R Chade, Meike Kasten, Benjamin Priestley, Kelvin L Chou, Hubert H Fernandez, Franca Cambi, J William Langston and Caroline M Tanner. Annals of Neurology; Published Online: November 14, 2011 (DOI:10.1002/ana.22629).

Related Stories

Recommended for you

Parkinson's disease reverted at a experimental stage

Dec 19, 2014

Mexican scientists demonstrated experimentally, with adult rats, that mobility can be restored in patients with Parkinson's disease, the major degenerative disease of the motor system worldwide. The experiments ...

EU team launches clinical trial of Parkinson's vaccine

Dec 09, 2014

Today the EU-consortium SYMPATH starts recruitment for a Phase I study of a Parkinson's vaccine candidate called AFFITOPE PD03A. This vaccine is one out of a designated pool of promising vaccine candidates based on AFFiRiS' ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.